scispace - formally typeset
Y

Ying Li

Researcher at Texas A&M University

Publications -  236
Citations -  15663

Ying Li is an academic researcher from Texas A&M University. The author has contributed to research in topics: Medicine & Catalysis. The author has an hindex of 58, co-authored 195 publications receiving 12523 citations. Previous affiliations of Ying Li include North Carolina State University & Arizona State University.

Papers
More filters
Journal ArticleDOI

Aptamers evolved from live cells as effective molecular probes for cancer study

TL;DR: A group of aptamers have been generated for the specific recognition of leukemia cells that can specifically recognize target leukemia cells mixed with normal human bone marrow aspirates and can also identify cancer cells closely related to the target cell line in real clinical specimens.
Journal ArticleDOI

Photocatalytic CO2 Reduction with H2O on TiO2 Nanocrystals: Comparison of Anatase, Rutile, and Brookite Polymorphs and Exploration of Surface Chemistry

TL;DR: In this article, the authors studied CO2 photoreduction with water vapor on three TiO2 nanocrystal polymorphs (anatase, rutile, and brookite) that were engineered with defect-free and oxygen-deficient surfaces.
Journal ArticleDOI

Engineering Coexposed {001} and {101} Facets in Oxygen-Deficient TiO2 Nanocrystals for Enhanced CO2 Photoreduction under Visible Light

TL;DR: In this paper, a blue TiO2 nanocrystals with coexposed {101}-{001} facets was reported to enhance CO2 photoreduction under visible light.
Journal ArticleDOI

Photocatalytic reduction of CO2 with H2O on mesoporous silica supported Cu/TiO2 catalysts

TL;DR: In this article, mesoporous silica supported Cu/TiO 2 nanocomposites were synthesized through a one-pot sol-gel method, and the photoreduction experiments were carried out in a continuous-flow reactor using CO 2 and water vapor as the reactants under the irradiation of a Xe lamp.
Journal ArticleDOI

Cell-specific aptamer probes for membrane protein elucidation in cancer cells.

TL;DR: This two-step strategy, that is, first selecting cancer cell-specific aptamers and then identifying their binding target proteins, has major clinical implications in that the technique promises to substantially improve the overall effectiveness of biomarker discovery.